American Academy of Allergy, Asthma and Immunology

Do Patients Continue With Biologics for Asthma in Clinical Practice?

March 19, 2020

To optimize use of biologics for asthma, greater attention should be paid to adherence, according to an abstract prepared and published for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.

Researchers Evaluate Infusion Parameters for IgPro20

March 19, 2020

Two studies discussed the feasibility of different parameters for the infusion of a product for patients with primary immunodeficiency disorder in abstracts prepared for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.

Cost-Effectiveness, Impact of AIT on Costs Among Published AAAAI Research

March 18, 2020

Is it cost-effective to prescribe epinephrine to every patient on allergen immunotherapy (AIT)? Does AIT have an impact on healthcare costs? These and other issues were included among the research prepared and published for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.

IgPro20 Well Tolerated by Most Patients With PID, According to Phase 4 Study Data

March 18, 2020

High infusion parameters for pump-assisted and manual push 20% subcutaneous immunoglobulin (SCIg), or IgPro20, were well tolerated by patients with primary immunodeficiency disorder (PID), according to a recent abstract prepared for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.

Research Examines Factors That Complicate Pediatric Asthma

March 18, 2020

Included among the abstracts prepared and published for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting are several that looked at the clinical and psychosocial factors that complicate asthma in pediatric patients. A few are highlighted here.

First Patients Receive Aimmune Therapeutics' Peanut Allergy Treatment Palforzia

March 16, 2020

The first US patients with peanut allergy have been treated with Aimmune Therapeutic’s Palforzia oral immunotherapy (OIT), the company said. The treatment was approved by the FDA in January, and is the first approved treatment for patients with peanut allergy.

Q&A: Research Shows Struggles to Improve Indoor Air Quality in Childcare Centers

March 14, 2020

The American Journal of Managed Care® discussed the prevalence of poor indoor air quality in childcare facilities with Joshua Steinberg, MD, assistant professor of pediatrics at the Medical College of Wisconsin, and Erin Lee, a clinical research coordinator at the Medical College of Wisconsin.

A Q&A on the Efficacy of Ragweed SLIT Tablets in Children

March 14, 2020

The American Journal of Managed Care® (AJMC®) dicussed the efficacy of ragweed sublingual immunotherapy (SLIT) tablets with Anne Ellis, MD, professor of medicine and chair of the Division of Allergy & Immunology at Queen's University in Kingston, Ontario, Canada.

A Q&A on How Genotypes, Secondhand Smoke Exposure Impact Asthma

March 14, 2020

The American Journal of Managed Care® (AJMC®) interviewed Elisabet Johansson, PhD, a research fellow at the University of Cincinnati, about how the gene NFE2L2 interacts with secondhand smoke, and increases the risk of asthma.